An Exploratory Phase 2 Study Evaluating the Efficacy and Safety of Fibrin Sealant, Vapor Heated, Solvent/Detergent Treated (FS VH S/D) 500 S-APR for the Sealing of Dura Defect Sutures in Posterior Fossa Surgery
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Pathological Processes in the Posterior Fossa
- Sponsor
- Baxter Healthcare Corporation
- Enrollment
- 95
- Primary Endpoint
- Incidence of Cerebrospinal Fluid (CSF) Leakage Observed After Surgery
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of this study is to investigate the efficacy and safety of FS VH S/D 500 s-apr, a double virus-inactivated biological two-component fibrin sealant, for use in posterior fossa surgery as an adjunct to dura and dura substitute sutures in preventing postoperative cerebrospinal fluid (CSF) leakage.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Preoperative Inclusion Criteria:
- •Subjects undergoing elective craniotomy / craniectomy for pathological processes in the posterior fossa (such as benign and malignant tumors, vascular malformations, and Chiari 1 malformations) that result in dura defects requiring dura substitution for closure and who are able and willing to comply with the procedures required by the protocol
- •Signed and dated written informed consent from the subject or from his/her legal representative prior to any study-related procedures
- •Age \>= 3 years, either gender
- •Intraoperative Inclusion Criteria:
- •Surgical Wound Classification Class I and Risk Index Category (RIC) \<=
- •Penetration of mastoid air cells during partial mastoidectomy is permitted and will be recorded.
- •A patch of autologous fascia or pericranium or suturable collagen-based dura substitute was cut to size and then sutured into the dura defect.
- •The hem of native dura exposed along and under the craniotomy edge is wide enough to facilitate suturing and to allow for sufficient surface area for adherence of the investigational product.
Exclusion Criteria
- •Preoperative Exclusion Criteria:
- •Female subjects who are breastfeeding, pregnant, or intend to become pregnant during the clinical study period
- •Subjects with a dura lesion from a recent surgery that still has the potential for cerebrospinal fluid (CSF) leakage unless it can be expected that the lesion will be excised completely, including all old suture holes
- •Chemotherapy scheduled within 7 days following surgery
- •Radiation therapy to the head scheduled within 7 days following surgery
- •Subjects with severely altered renal (serum creatinine \> 2 mg/dL) and/or hepatic function \[ALT, AST \> 5 x upper limit of norm (ULN)\]
- •Evidence of an infection indicated by any one of the following: fever \> 101°F, white blood cell (WBC) count \< 3500/μL or \> 13000/μL, positive blood culture, positive chest X-ray. A positive urine culture (\> 10\^5 colony-forming units (CFU)/mL) leads to exclusion unless acute cystitis is the sole cause. Evidence of infection along the planned surgical path. A WBC count of \< 20000/μL is permitted if the patient is being treated with steroids in the absence of all the other infection parameters.
- •Conditions compromising the immune system; existence of autoimmune disease
- •Known hypersensitivity to aprotinin or other components of the investigational product
- •Non-compliant or insufficient treatment of diabetes mellitus \[glycosylated hemoglobin (HbA1c) \> 7.5%\]
Outcomes
Primary Outcomes
Incidence of Cerebrospinal Fluid (CSF) Leakage Observed After Surgery
Time Frame: 33 +/- 3 days after surgery
Study-relevant CSF leakage is defined as one or more of following: 1. Discrete subcutaneous or subgaleal CSF collection (pseudomeningocele) in surgical area confirmed by positive test for β2-transferrin, or by computed tomography (CT) or magnetic resonance imaging (MRI) 2. Epidural CSF collection in surgical area depicted by CT or MRI 3. Leakage of CSF through surgical wound observed during physical examination, confirmed by a positive test for β2-transferrin 4. Progressive pneumatocephalus (air in subarachnoidal space) depicted by repeat CT in absence of CSF drainage.
Number of Participants With Cerebrospinal Fluid (CSF) Leakage Observed After Surgery
Time Frame: 33 +/- 3 days after surgery
Study-relevant CSF leakage is defined as one or more of following: 1. Discrete subcutaneous or subgaleal CSF collection (pseudomeningocele) in surgical area confirmed by positive test for β2-transferrin, or by computed tomography (CT) or magnetic resonance imaging (MRI) 2. Epidural CSF collection in surgical area depicted by CT or MRI 3. Leakage of CSF through surgical wound observed during physical examination, confirmed by a positive test for β2-transferrin 4. Progressive pneumatocephalus (air in subarachnoidal space) depicted by repeat CT in absence of CSF drainage.
Secondary Outcomes
- Incidence of Procedures Resulting From the Treatment of CSF Leaks(until resolution or 30 days after final follow-up visit (Day 33+/-3), whichever is first)
- Number of Participants With Procedures Resulting From the Treatment of CSF Leaks(until resolution or 30 days after final follow-up visit (Day 33+/-3), whichever is first)
- Incidence of Surgical Site Infections (SSI) According to National Nosocomial Infection Surveillance (NNIS) Criteria(within 1 month following surgery)
- Number of Participants With Surgical Site Infections (SSI) According to National Nosocomial Infection Surveillance (NNIS) Criteria(within 1 month following surgery)